Stocks · Healthcare · Biotechnology
Eikon Therapeutics, Inc. Common Stock EIKN
$7.33 -1.08% Close, Oct 2, 2026 · NASDAQ · Market cap $396.8M
Expensive vs sector
Next earnings report: Nov 12, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- The stock is 55% below its highest close of the past year.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 5, 2026.
How fast revenue, earnings and cash flow are growing.
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalBottom 28%
- Accruals (lower is better)Top 40%
How cheap the shares are relative to earnings, cash flow and their own history.
- Free-cash-flow yieldBottom 6%
- EBITDA / enterprise valueBottom 9%
Strength and persistence of the price trend, including versus the S&P 500.
- 6-month returnBottom 19%
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersBottom 5%
- Consecutive EPS beatsBottom 20%
- Upside to consensus price targetBottom 1%
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Bottom 15%
- Maximum drawdown, 3 yearsTop 28%
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Return on invested capital | -46.2% | — | Bottom 28% |
Quality of earnings and balance sheet
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- -8.5%
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- -88.37%
- Shareholder yield
- -88.37%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Aug 13, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 0
- Beats in the last 8 reports
- 0 of 3
- Average EPS surprise, last 4
- -100.0%
- Average 2-day reaction, last 8
- -0.8%
- Positive 20 days after report
- 0 of 3
Analysts
- Consensus price target
- $5.00
- Target vs current price
- -31.8%
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Aug 13, 2026 | -3.2% | -0.9% | +15.3% | -11.6% | — |
| May 11, 2026 | -67.3% | -0.1% | +33.0% | -9.8% | -4.1% |
| Mar 30, 2026 | -658.4% | -1.3% | -3.8% | -10.9% | -1.8% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Aug 13, 2026 | -$1.63 | -$1.58 | -3.2% | — |
| May 11, 2026 | -$2.46 | -$1.47 | -67.3% | — |
| Mar 30, 2026 | -$27.00 | -$3.56 | -658.4% | — |
| Dec 3, 2025 | -$11.50 | — | — | — |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| Free-cash-flow yield | -65.32% | — | — | Bottom 6% |
Technical state
Trend checklist
- ✗ Price above 20-day average
- ✗ Price above 50-day average
- ✗ MACD histogram positive
Trend quality
- Days above the 50-day average
- 0
- 50-day average slope (20 days)
- -7.7%
- Distance from 50-day average
- -25.0%
- RSI (14)
- 31.9
- Relative volume
- 0.62×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 83.6%
- Current drawdown from 1-year high
- -54.9%
- Maximum drawdown, 3 years
- -54.9%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Feb 18, 2026 | Oct 2, 2026 | -54.9% | 157 days | Not yet recovered |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $396.8M
- Revenue (TTM)
- $0
| FY 2025 | |
|---|---|
| Revenue | $0 |
| Gross profit | -$24.2M |
| Operating income | -$338.9M |
| Net income | -$324.2M |
| EPS (diluted) | -$6.16 |
| Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net income | -$71.1M | -$79.7M | -$83.0M | -$88.4M |
| EPS (diluted) | — | -$1.47 | -$1.53 | -$1.63 |
| FY 2025 | |
|---|---|
| Operating cash flow | -$188.5M |
| Capital expenditure | -$46.7M |
| Free cash flow | -$235.3M |
| Dividends paid | $0 |
| Net share buybacks | $1.9M |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $531.6M
- Total assets
- $779.6M
- Total liabilities
- $313.1M
- Total debt
- $252.2M
- Net debt
- $109.2M
- Shareholders’ equity
- $466.5M
As of Jun 30, 2026 (filed Aug 13, 2026).
Short interest
- Shares sold short
- 5,452,560
- Days to cover
- 9.26
- Change vs previous report
- +3.3%
FINRA short interest, settlement date Sep 15, 2026.